Epidemiology of atherothrombotic disease and the effectiveness and risks of antiplatelet therapy: Race and ethnicity considerations

Cardiology in Review

Volumn 16, Issue 2, 2008, Pages 82-88

  Saunders, Elijah ^a   Ofili, Elizabeth ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Antiplatelet therapy; Atherothrombosis; Ethnicity; Risk reduction

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; TICLOPIDINE; WARFARIN;

ARTERY DISEASE; ATHEROTHROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED DRUG RELEASE; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; ETHNIC DIFFERENCE; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HEALTH CARE COST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC HEART DISEASE; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SOCIOECONOMICS; STROKE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK REDUCTION BEHAVIOR; THROMBOSIS;

EID: 39449135695     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31815685fa     Document Type: Review

References (60)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.
2. US Census Bureau. US Census Bureau Race Data. Available at: http://www.census.gov/population/www/socdemo/race.html. Accessed April 26, 2005.
3. Munger MA, Hawkins DW. Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc. (Washington, DC) 2004;44:S5-S12; quiz S12-S13.
4. Duvall WL, Vorchheimer DA. Multi-bed vascular disease and atherothrombosis: scope of the problem. J Thromb Thrombolysis. 2004;17:51-61.
5. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches. Vasc Med. 1998;3:231-239.
6. Rauch U, Osende JI, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med. 2001;134:224-238.
7. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.
8. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588-636.
9. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-1374.
10. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:513S-548S.
11. Menon V, Harrington RA, Hochman JS, et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:549S-575S.
12. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201-206.
13. Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:609S-626S.
14. Hanley D, Gorelick PB, Elliot WJ, et al. Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: a guideline for primary care physicians from the National Stroke Association Work Group on recurrent stroke prevention. J Stroke Cerebrovasc Dis. 2004;14:1-12.
15. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 2001;32:280-299.
16. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Available at: http://www.americanheart.org/presenter.jhtml?identifier= 1928. Accessed March 2, 2005.
17. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736-743.
18. Sacco RL, Boden-Albala B, Gan R, et al. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol. 1998;147:259-268.
19. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29:415-421.
20. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110:738-743.
21. Criqui MH, Vargas V, Denenberg JO, et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation. 2005;112:2703-2707.
22. Fabsitz RR, Sidawy AN, Go O, et al. Prevalence of peripheral arterial disease and associated risk factors in American Indians: the Strong Heart Study. Am J Epidemiol. 1999;149:330-338.
23. Kaplan NM. Ethnic aspects of hypertension. Lancet. 1994;344:450-452.
24. Saunders E. Hypertension in African-Americans. Circulation. 1991;83:1465-1467.
25. Liao Y, Ghali JK, Berzins L, et al. Coronary angiographic findings in African-American and white patients from a single institution. J Natl Med Assoc. 2001;93:465-474.
26. Tang W, Detrano RC, Brezden OS, et al. Racial differences in coronary calcium prevalence among high-risk adults. Am J Cardiol. 1995;75:1088-1091.
27. Budoff MJ, Yang TP, Shavelle RM, et al. Ethnic differences in coronary atherosclerosis. J Am Coll Cardiol. 2002;39:408-412.
28. Bild DE, Detrano R, Peterson D, et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2005;111:1313-1320.
29. Budoff MJ, Nasir K, Mao S, et al. Ethnic differences of the presence and severity of coronary atherosclerosis. Atherosclerosis. 2006;187:343-350.
30. Kawakubo M, LaBree L, Xiang M, et al. Race-ethnic differences in the extent, prevalence, and progression of coronary calcium. Ethn Dis. 2005;15:198-204.
31. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003;52:1799-1805.
32. Lutsey PL, Cushman M, Steffen LM, et al. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost. 2006;4:2629-2635.
33. LaMonte MJ, Durstine JL, Yanowitz FG, et al. Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women. Circulation. 2002;106:403-406.
34. Wong ND, Pio J, Valencia R, et al. Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) III. Prev Cardiol. 2001;4:109-114.
35. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138:S419-S420.
36. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378-3384.
37. Watson KE, Topol EJ. Pathobiology of atherosclerosis: are there racial and ethnic differences? Rev Cardiovasc Med. 2004;5(Suppl 3):S14-S21.
38. Sabatine MS, Blake GJ, Drazner MH, et al. Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. Circulation. 2005;111:1217-1224.
39. Lurie N, Fremont A, Jain AK, et al. Racial and ethnic disparities in care: the perspectives of cardiologists. Circulation. 2005;111:1264-1269.
40. Sonel AF, Good CB, Mulgund J, et al. Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines? ). Circulation. 2005;111:1225-1232.
41. Rathore SS, Berger AK, Weinfurt KP, et al. Race, sex, poverty, and the medical treatment of acute myocardial infarction in the elderly. Circulation. 2000;102:642-648.
42. Shahar E, Folsom AR, Romm FJ, et al. Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 1996;131:915-922.
43. Jha AK, Varosy PD, Kanaya AM, et al. Differences in medical care and disease outcomes among black and white women with heart disease. Circulation. 2003;108:1089-1094.
44. Christian JB, Lapane KL, Toppa RS. Racial disparities in receipt of secondary stroke prevention agents among US nursing home residents. Stroke. 2003;34:2693-2697.
45. Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2001;24:197-201.
46. Petersen LA, Wright SM, Peterson ED, et al. Impact of race on cardiac care and outcomes in veterans with acute myocardial infarction. Med Care. 2002;40:I86-I96.
47. Chen Z. COMMIT/CCS-2: Clopidogrel and Metoprolol in Myocardial Infarction Trial/Second Chinese Cardiac Study - the clopidogrel arm. Available at: http://www.medscape.com/viewarticle/501637. Accessed May 2005.
48. Kuo PI, Severino R, Pashkow FJ. Mortality rates and hemorrhagic complications in asian-pacific islanders during treatment of acute myocardial infarction. Am J Cardiol. 2004;94:644-646, A649.
49. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA. 2003;289:2947-2957.
50. Weisberg LA. The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. Neurology. 1993;43:27-31.
51. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641-1649.
52. Falluji N, Steinhubl SR. Variable response to antiplatelet therapy: what does it mean to clinicians? Cleve Clin J Med. 2007;74:49-55.
53. Farrell TP, Hayes KB, Sobel BE, et al. The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine. Am J Cardiol. 1999;83:770-774.
54. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-235.
55. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45:246-251.
56. Mikkelsson J, Perola M, Penttila A, et al. The GPIIIa (beta3 integrin) PlA polymorphism in the early development of coronary atherosclerosis. Atherosclerosis. 2001;154:721-727.
57. Curtin R, Fitzgerald DJ. Pharmacogenetics of antiplatelet drugs. ScientificWorldJournal. 2002;2:791-800.
58. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006;367:651-658.
59. Kunicki TJ. The role of platelet collagen receptor (glycoprotein Ia/IIa; integrin alpha2 beta1) polymorphisms in thrombotic disease. Curr Opin Hematol. 2001;8:277-285.
60. Kenny D, Muckian C, Fitzgerald DJ, et al. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. J Thromb Thrombolysis. 2002;13:13-19.